A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD

NCT04571164 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

294

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: LY03003(Rotigotine,extended-release microspheres)
DRUG: Placebo,extended-release microspheres

Sponsor

Luye Pharma Group Ltd.

Collaborators

[object Object]